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Serum was obtained from 25 male renal cell carcinoma (RCC) patients and 21 healthy males. O-glycans were released by a 
-elimination reaction and purified by graphitized carbon cartridge solid phase extraction, then profiled by matrix-assisted la-
ser desorption/ionisation-time of flight mass spectrometry. After noise removal and peak alignment, 1372 peaks were extracted 
from 200000 data points. Feature peaks were analyzed by calculation of differential sensitivity and specificity. The combina-
tion of two feature peaks was chosen as a biomarker and could clearly differentiate RCC and normal samples in our study 
group. 
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Approximately 210000 cases of renal cell carcinoma (RCC) 
are diagnosed annually worldwide, accounting for 102000 
deaths [1]. In the European Union and United States, RCC 
is the ninth most common cancer [2], while it is the sixth 
most common cancer in China [3]. Local RCC incidence 
increased from 0.4 per 1000 in 2000 to 0.6 in 2010 [3], and 
has become an important threat to health in China. Envi-
ronmental risk factors are considered as major causes for 
the increase in the past 10 years. The five-year survival rate 
of RCC is over 50% in patients without distant metastases; 
however five-year survival falls to less than 10% in cases of 
distant metastases [4]. Because there are currently no avail-
able biomarkers for RCC, one-third of patients are found to 
have metastasis at first diagnosis [5]. Sensitive and conven-
ient RCC screening can greatly improve prognosis and 
five-year survival; therefore efforts to improve screening 
methods are urgently required in RCC research. 
Protein glycosylation is one of the most important 
post-translational modifications (PTMs), and over 50% 
proteins are glycosylated [6]. Glycans attached to proteins 
have very important functions in cancer biology. Glycan 
changes occur in all stages of tumor progression, including 
proliferation, invasion, angiogenesis, metastasis and im-
munity [7]. Therefore, changes in glycans are a hallmark of 
cancer states [8]. With rapid developments in mass spec-
trometry, glycans can now be profiled. Moreover, they are 
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easier to identify and quantify compared with proteins be-
cause of their smaller molecular weight and greater stability 
[9]. All these factors make glycans appropriate potential 
biomarkers [10] for cancer. 
Many studies have investigated glycan cancer bi-
omarkers in recent years. The majority focused on N-linked 
glycans [11–13], because there is no broad-spectrum glyco-
sidase for O-glycosylation, and this hinders O-glycan bi-
omarker studies. In fact, both O-linked glycans and 
N-linked glycans are important in cancer. Mucins (MUC) 
are used as cancer biomarkers in many cancers that are 
characterized by dense clusters of O-linked glycans, and 
MUC1 is highly overexpressed in RCC [14,15]. Examina-
tion of O-glycan changes by serum O-glycan profiling will 
lead to new strategies for RCC biomarker discovery. 
In this research, O-linked glycans were released by 
-elimination and purified through graphitized carbon solid-    
phase extraction cartridges for mass spectra analysis [16]. 
Because there was no high-performance liquid chromatog-
raphy separation section, the experimental time was consid-
erably smaller. This would be beneficial in further large 
sample size validation. 
1  Materials and methods 
1.1  Human serum sample preparation 
Serum samples from healthy male individuals (n=21) and 
male patients with histologically confirmed RCC (n=25) 
were obtained from the Shanghai Municipal Center for Dis-
ease Control & Prevention (Shanghai CDC) and Shanghai 
Changzheng Hospital, respectively. All samples were pro-
cessed as follows: blood samples were first incubated in 
anticoagulant-free tubes at 37°C for 1 h, and then centri-
fuged at 2400×g or 10 min. The supernatant was collected 
and stored at 80°C as serum samples for subsequent ex-
periments. 
1.2  Release of O-glycans 
A total of 10 L serum was mixed with 10 L 2 mol L1 
NaBH4 (China National Pharmaceutical Group Co., Shanghai, 
China) in 0.1 mol L1 NaOH (Sinopharm Chemical Reagent 
Co., Ltd). This mixture was incubated at 42°C for 18 h, and 
then 1 mol L1 HCl (China National Pharmaceutical Group) 
was slowly added until the pH was between 3 and 5 to 
quench the reaction. The solution was centrifuged at 
2400×g for 5 min at 4°C, and the supernatant was diluted to 
200 L and subjected to solid-phase extraction for oligo-
saccharide purification and enrichment. 
1.3  Solid-phase extraction (SPE) of O-glycans 
Solid-phase extraction was performed using graphitized car-
bon cartridges (Alltech Associates, Inc., Chicago, Illinois, 
USA). Cartridges were preconditioned with 1 mL ACN/H2O 
(80%/20%, v/v) mixture containing 0.05% chromatograph-
ically pure TFA (Sigma-Aldrich Co. Ltd., Gillingham, UK) 
at a flow rate of 0.5 mL min1, followed by 2 mL H2O at the 
flow rate of 0.5 mL min1. In the loading phase, 200 μL 
-elimination product was added and the cartridge was 
slowly rotated approximately 3–6 times without external 
pressure. In the desalting phase, 5 mL H2O was worked 
through the column at a flow rate of 0.5 mL min1. Then   
1 mL 10% ACN (China National Pharmaceutical Group) 
was eluted at a flow rate of 0.5 mL min1. The eluate was 
collected and concentrated to 10 L for mass spectrometry 
(MS) analysis. 
1.4  Mass spectrometry  
Mass spectra with an external matrix-assisted laser desorp-
tion/ionization (MALDI) source were carried out on Bruker 
Ultraflex III TOF/TOF (Bruker Daltonics, Billerica, Mas-
sachusetts, USA) at positive ion mode. Purified glycan 
samples were combined in a 1:1 ratio with 2,5-dihydro-     
xybenzoic acid (DHB) matrix solution. The matrix solution 
was prepared by 10 mg DHB in 1 mL 50% ACN/H2O (v/v). 
Mass spectra were controlled by FlexControl 3.3 software 
(Bruker Daltonics) using the following parameters: 25 kV 
acceleration voltage, 21.85 kV pulse voltage, 30 ns ion ex-
traction delay, and 1.4 kV detector gain. Results were ana-
lyzed using FlexAnalysis 3.3 software (Bruker Daltonics 
Ins). The data were collected and imaged using FlexImag-
ing 3.0 software (Bruker Daltonics). 
1.5  Raw mass data processing 
Detection of signals from raw data consisted of two parts: 
peak detection from single mass spectrum and peak align-
ment among multiple spectra. Peak detection from single 
mass spectrum was performed using the following steps: 
peak finding, chemical noise removal, normalization and 
deisotoping. Undecimated discrete wavelet transform 
(UDWT) was applied to remove the high frequency random 
noise from the MALDI-TOF data. The baseline was cor-
rected by linear interpolation and chemical noise was re-
moved by a robust regression method. 
After removal of the chemical noise, peak heights were 
used to estimate the abundance for every glycan peak. Median 
normalization was applied to eliminate the system error. 
Finally, the isotope clusters were identified by detecting 
whether the distance between two peaks was within (1±0.2) 
Da, and the highest peak among an isotope cluster was se-
lected. 
If the distance between two peaks from different spectra 
was within 0.25 to 0.25 Da, the two peaks were viewed as 
a MS signal from the same glycan in different spectra. All 
peaks were aligned using the aforementioned principle. 
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2  Results and discussion 
2.1  MALDI-TOF data processing 
Because matrix-assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF MS) offers a simple 
means for screening complex mixtures [17], it plays a cru-
cial role in the characterization of glycosylation [18]. Peak 
detection is a pivotal first step in biomarker discovery. It is 
not only an important extraction step but also indispensable 
for subsequent glycan identification and quantification, and 
can significantly influence the results of downstream data 
analysis steps. Hence processing of MALDI-TOF MS raw 
data is a central issue for glycan biomarker analysis. 
The MALDI-TOF MS raw data consists of the possible 
peak signal, random noise and chemical noise. Random 
noise is normally high frequency noise caused by the in-
strument. Chemical noise is low frequency noise, resulting 
from the response to MALDI matrix and chemical reagents. 
Chemical noise peaks are separated by a little more than   
1 Da, and sinusoidal in shape. Removal of chemical noise 
and random noise significantly improves the signal-to-noise 
ratio (SNR). 
Figure 1 shows the TOF data. Chemical noise signals have 
the same pattern. Peak intensity exhibited some variation 
locally, and decreased with increasing m/z. Spectrum features 
were similar to Q-TOF data [19] and prOTOF data [20]. 
Peak detection from single mass spectra includes peak 
identification, chemical noise removal, normalization and 
deisotoping. Figure 2 gives a concrete example of peak 
identification and chemical noise removal. In this glycomic 
experiment, a large quantity of MS data were generated. 
Each mass spectrum consisted of more 200000 data points. 
It was very difficult to perform biomarker analysis directly 
on the raw MS data. Following an existing analytic ap-
proach [21], high frequency random noise was first re-
moved by the undecimated discrete wavelet transform 
(UDWT) method. Then, the baseline was corrected using 
linear interpolation. Finally, the local maximum of N 
neighboring points was viewed as the peak. It is worth not-
ing that the peaks obtained using this method were not only 
the glycan peaks, but also the chemical noise peaks. 
The robust regression method [19] was applied to detect 
glycan peaks from chemical noise. This method views the 
glycan peaks as outliers of chemical noise distributions. 
Because the robust regression method includes the effect of 
outliers, a linear robust regression model is used to estimate 
the intensity distribution and the location distribution of 
chemical noise peaks. First, using all peaks intensities, a 
linear robust regression model, 
( / ) ( / ),I m z a b m z    
was formed to estimate the relationship between the chemi-
cal noise intensity I and m/z. The parameters a and b were 
estimated by the robust regression method. Peaks with in-
tensities exceeding 0.2I were retained. In contrast, chemi-
cal noise peaks are separated by approximately 1 Da, and 
this frequency is nearly constant over the entire m/z range. 
The glycan peaks may not share this pattern. Second, a ro-
bust M-type regression model, 
( / ) ( / ),M m z a b m z    
was fitted to estimate the relationship between the location  
 
 
Figure 1  A raw spectrum, including the true or possible peak signal, chemical noise and random noise. 
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Figure 2  An example of the peak finding, chemical noise removal and 
deisotope process. A, The spectrum after peak finding. The blue line shows 
the spectrum after UDWT denoising and baseline removal, the cyan line 
shows the chemical noise peaks, and the red line shows the true peaks. B, 
Peaks after chemical noise removal (red line). C, Peaks after deisotope (red 
line). 
offset M and m/z. The parameters a and b were estimated 
by using the peaks with intensities greater than 0.2 I based 
on the robust regression method. The standard deviation 
M(m/z) of robust regression can be used to detect glycan 
peaks. The peaks with large M(m/z) deviate from the loca-
tion distribution of chemical noise peaks. Peaks with stu-
dentized residuals that exceed 2.5 are glycan peaks. Last, a 
linear robust regression model, 
( / ) ( / ),I m z a b m z    
was applied to estimate the relatioship between the chemical 
noise intensity I and m/z for the glycan peaks. The param-
eters a and b could also be estimated by the robust regres-
sion method. The standard deviation I(m/z) of robust re-
gression is used to detect glycan peaks. Peaks with large 
I(m/z) deviate from the intensity distribution of chemical 
noise peaks. If the studentized residual of a peak exceeds 
2.35, the peak is classed as a glycan peak. Using the robust 
regression method, the glycan peaks were detected and the 
default parameters for this method were selected. 
Figure 2 shows the peak detection results, in which the 
red line shows the true peaks and the cyan line shows the 
chemical noise peaks. It is clear that the mass spectrum 
quality was greatly improved and peak complexity was 
greatly reduced after noise removal. Finally, 1372 peaks 
were extracted from 200000 data points. 
2.2  Analysis of serum glycans 
In total, 25 serum samples of serum from renal cell carci-
noma patients (group A) and 21 serum samples from 
healthy individuals were taken (group B). Peak quantitative 
character (peak intensity) and peak qualitative character 
(peak exists only in one group) were evaluated as differen-
tiation markers. Qualitative character was more effective 
and was chosen as the differentiation character in this study 
(data not shown). 
If one glycan peak appearing in group A alone can de-
termine a sample as RCC, the sensitivity is NA/25 and the 
specificity is 1NB/21. Similarly, if one glycan peak ap-
pearing in group B alone can determine a sample as normal, 
the sensitivity is NB/21 and the specificity is 1NA/25. 
Only peaks in group A or group B with peak sensitivity 
greater than 50% were considered. Thus the peak coverage 
threshold in group A and B should be above 55.2% (13/25) 
and 52.38% (11/21), respectively. When combining the 
peaks eligible for two conditions, 110 peaks were screened 
out from a total of 1372 peaks. 
Peak sensitivity and specificity were calculated for 110 
peaks selected in the first screening. Specificity was con-
sidered as a more important parameter because it can con-
trol the false positive ratio. The threshold of specificity was 
set at 80%. There were five peaks whose specificity was 
above 80%; four peaks were indicators for the normal state 
and one peak was an indicator for RCC state, with P72 as 
the peak with the best differentiation performance. Detailed 
information of the sensitivity and specificity of these five 
peaks is shown in Table 1. 
Differentiation performance was evaluated by visualiza-
tion. We randomly took a pair of RCC and normal O-glycan 
profiles as examples. In Figure 3, the marked peaks are the 
obtained peaks in the above analysis, and these five peaks 
could clearly differentiate between RCC and the normal 
state. Also, the average feature peak intensity was calculat-
ed for both RCC and the normal group. Average peak inten-
sity is represented by different shade of colors in Figure 4. 
The five marked peaks clearly showed major differences 
between RCC and the normal group. 
Unfortunately, sensitivity was not very high (Table 1) 
when the five different peaks were individually considered 
as biomarkers. However, when we combined two or more 
peaks as an indicator of disease state, the sensitivity was 
significantly improved. The combination of P72 and P47 
was taken as a potential biomarker, and thus in this com-
bined model the appearance of either P21 or P47 could 
identify the normal state. The sensitivity and specificity of 
this combination was calculated. 
Table 1  Feature peaks (specificity>80%) 
Peak ID Observed m/z Marker type Sensitivity Specificity 
P26 686.38 Normal 57.14% (12/21) 84.00% (21/25) 
P33 727.33 Normal 52.38% (11/21) 80.00% (20/25) 
P47 823.41 Normal 61.90% (13/21) 84.00% (21/25) 
P72 1017.57 Normal 57.14% (12/21) 96.00% (24/25) 
P93 1193.61 RCC 56.00% (14/25) 80.95% (17/21) 
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Figure 3  MS spectrum of RCC and normal state.  
 
Figure 4  Average peak intensity MS spectrum heat map of RCC and normal group. 
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Sensitivity was as high as 83.67%, while specificity was 
still 80.64% (above 80%). 
3  Conclusion 
In this research for the first time, we applied a glycomic 
approach to obtain O-glycan MS profiling of RCC and 
normal serum. A series of mass spectrum data processing 
was performed and spikes in MS data were analyzed. A 
combination of two MS peaks was chosen as a biomarker to 
differentiate between RCC and normal samples, and en-
sured optimal performance in our small sample size. In the 
future we will expand the sample size and also analyze the 
glycan structure. 
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